주 메뉴 바로가기 본문 바로가기 하단 바로가기

Celebrating the beginning of the biosimilar era When the biosimilar industry was newly emerging, Celltrion Healthcare established strategic relationship with Celltrion as co-developer with strong conviction that the biosimilar business would be successful. In 2013, Remsima®, the world’s first biosimilar monoclonal antibody, was launched in Europe that led the global pharmaceutical market, bringing the significance of biosimilars to worldwide attention.

1999~2009 history image
1999.12
Established Nexol Inc
2008.08
Established Global distribution agreement with Celltrion
2012~2013 history image
2009.03
Changed the company name to Celltrion Healthcare
2013.09
Launched Remsima® in Europe

Proving the potential success of biosimilars The total cumulative export value of Remsima® reached KRW 1 trillion in 2016, which was a great achievement in the biopharmaceutical history of Korea. In addition, Celltrion Healthcare managed to launch Remsima®(Inflectra®) in the United States, which is known for having the world’s top pharmaceutical market, and Truxima®, the world's first oncology mAB biosimilar, in Europe, proving that biosimilars have the potential for success in the global markets.

2015~2017 history image
2015.12
Won the “USD 30 Billion Trade Award” at the 52nd Annual Trade Day
2016.10
The total export value of Remsima® reached KRW 1 trillion
2016.12
Launched Remsima®(Inflectra®) in the United States
2017 history image
2017.04
Launched Truxima® in Europe
2017.06
Celltrion Healthcare listed on KOSDAQ
2017.12
The market share of Remsima® bypassed that of the originator medicine as a biosimilar for the first time in Europe.

Becoming the world’s leading bio-company The biosimilar market has led the global healthcare industry and been recognized for its financial value and growth potential. Celltrion Healthcare, which brought success to biosimilars, is now taking a bold step into becoming a direct seller of pharmaceuticals to the world.

2018 history image
2018.05
Launched Herzuma® in Europe
2019.11
Launched Truxima® in the United States
2019.11
RemsimaSC® is approved by Europe (EMA)
2020.02
Launched RemsimaSC® in Europe
Brazil Herzuma Launching Symposium
2020.03
Launched Herzuma® in the United States